ClinicalTrials.gov
ClinicalTrials.gov Menu

Epidemiology and Genetics of the Amyotrophic Lateral Sclerosis in the French West Indies (SLA-DOM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03367650
Recruitment Status : Recruiting
First Posted : December 11, 2017
Last Update Posted : December 11, 2017
Sponsor:
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Pointe-a-Pitre

Brief Summary:

The diagnosis and the follow-up of the patients reached of SLA is centralized, since a few years, at the the Caribbean Reference center of the rare neurological diseases (CERCA labélisé in 2006) in Martinique and at the Unity of coverage of the neuromuscular Diseases, SLA and the rare neurological diseases (create in 2010) in Guadeloupe. Several phenotypic characteristics seemed to us to take out again data collected during the follow-up of the patients (26 in Guadeloupe, since the creation of the unity) in particular patients' high proportion of exceptionally long evolution (more than 10 years). Besides, we diagnosed several cases (10 cases in Guadeloupe since 2000) of association SLA- Parkinsonien Syndrome.

This association, considered as exceptional could establish a particular phenotypic entity which we would like to describe. We are interested also originally geographical of the patients, with the hypothesis that he could exist in the Antilles one or several geographical isolates of the disease allowing to lead a étiologique investigation in search of a possible genetic or environmental cause.


Condition or disease Intervention/treatment Phase
Amyotrophic Lateral Sclerosis Dietary Supplement: Blood sample and environmental survey Not Applicable

Detailed Description:

The amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive muscular paralysis due to degeneration of motor neurons in the primary motor cortex, corticospinal pathway, brain stem and spinal cord. The incidence is estimated at 2/100 000 per year and prevalence at approximately 4/100000.

Various clinical forms are described. The disease is fatal is 3-5 years on average.

The majority of cases are sporadic and of unknown origin but 5-10% are familial and present for 20% of them, mutations in the SOD1 (21q22.11) gene. Other genes have recently been implicated in ALS. Environmental toxic factors have been extensively researched. Beta-methylamino-L-alanine (BMAA), a neurotoxic nonprotein amino acid produced by most cyanobacteria, has been proposed to be the causative agent of the ALS-Parkinsonism Complex on the island of Guam in the Pacific Ocean.

Epidemiology and clinical features of ALS have never been studied in Caribbean countries.

The main purpose of the study will be to evaluate the incidence of ALS in Guadeloupe and Martinique.

Secondary purposes will be:

  1. to evaluate the presence of specific phenotypic features;
  2. to establish he prognosis of different clinical forms;
  3. to study the genes implicated in ALS and quantify theexposure to BMAA.

Since 2000, the diagnosis of ALS is made in about 20 patients per year in Guadeloupe and Martinique(for a total population of 800000 inhabitants) but the incidence and the clinical presentation of ALS in the French West Indiesare unknown.

The exceptional association of ALS and parkinsonism is regularly observed in Guadeloupe. We propose to perform a prospective descriptive and longitudinal epidemiological study to determine the incidence of ALSin the French West Indies. In parallel we will study the involvement of genetic andenvironmental toxic factors as etiological factor for this disease.

Primary outcome:

- the impact of ALS in Guadeloupe and Martinique

Secondary outcomes:

  • Assess the clinical characteristics (presence of phenotypic features?),
  • the prognosis of different clinical forms study,
  • to establish the genetic factors of the ALS and to search potential environmental factors

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Bi-centric epidemiological prospective, cross-sectional descriptive study coupled with a longitudinal study.
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Epidemiology and Genetics of the Amyotrophic Lateral Sclerosis in the French West Indies
Actual Study Start Date : May 13, 2014
Estimated Primary Completion Date : May 13, 2020
Estimated Study Completion Date : May 13, 2023


Arm Intervention/treatment
ALS's patients in Guadeloupe and Martinique

We shall determine:

  • Impact of ALS in Guadeloupe and Martinique
  • Prevalence of the ALS in Guadeloupe and Martinique on the duration of the study
  • The distribution of ALS various phenotypes in our population of patients.
  • We shall collect the date of the beginning of the symptoms of the SLA, the date of diagnosis of ALS, the date of death for the same individual and the origin of the death, the weight, the size, the albumin, CRP; in order to establish the forecast of the various clinical forms, the description of the evolution of the nutritional state.
  • Search for transfers of genes TARDBP, VCP, SOD1 known and involved in the disease
  • Search for possible environmental factors
Dietary Supplement: Blood sample and environmental survey
The intervention corresponds to a 10 ml of Blood sample and an environmental survey.




Primary Outcome Measures :
  1. the impact of amyotrophic lateral sclerosis in Guadeloupe and Martinique [ Time Frame: Through study completion, an average of 6 years ]
    Number of new cases per year.


Secondary Outcome Measures :
  1. Estimate prevalence of the ALS [ Time Frame: Through study completion, an average of 6 years ]
    Determine the total number of case of ALS diagnosed in Guadeloupe and Martinique on the duration of the study

  2. Clinical criteria of SLA [ Time Frame: Through study completion, an average of 9 years ]
    General, neurological, digestive clinical examination and cardiorespiratory complete and the realization of the score " ALS funtional rating scale "

  3. Study the genetic factors of the ALS [ Time Frame: Through study completion, an average of 9 years ]

    Search for transfers of genes TARDBP, VCP, SOD1:

    According to the genealogical data, we shall target the possible family forms to test at these patient's the various genes known and involved in the disease (transfers of the gene SOD1 (21q22.11), of the gene TARDBP (1p36.22) coding the protein TAR DNA-binding protein 43 (TDP-43) and of the gene VCP (9p13.3) coding for the protein Valosin Containing Protein).

    For the sporadic cases the analysis of these genes will be realized on the whole studied population.

    For the family cases the genetic study will be spread in the whole family.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient or third-party responsible for receiving information on the study and who signed informed consent ;
  • Patient age over 18 years;
  • Patient living in the Antilles;
  • Patient with ALS or SLP (primary lateral sclerosis, pure central form of ALS).

Exclusion Criteria:

  • Patient non-affiliated to the social security scheme ;
  • in case of difficulty of monitoring patient, exclusion of the longitudinal study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03367650


Contacts
Contact: Chantal LERUS, Director of Clinical Research 0590 93 46 86 ext (+590) chantal.lerus@chu-guadeloupe.fr
Contact: Valérie SOTER, Manager of Reseach 0590 93 46 86 ext (+590) valerie.soter@chu-guadeloupe.fr

Locations
Guadeloupe
Hospital University Center of Pointe-à-Pitre Recruiting
Pointe-à-Pitre, Guadeloupe, 97159
Contact: Chantal LERUS, Director of Clinical Research    0590 93 46 86 ext (+590)    chantal.lerus@chu-guadeloupe.fr   
Contact: Valérie SOTER, Manager of Reseach    0590 93 46 86 ext (+590)    valerie.soter@chu-guadeloupe.fr   
Principal Investigator: Alice DEMOLY, Neurologist         
Martinique
Hospital University Center of Martinique Recruiting
Fort-de-France, Martinique, 97261
Contact: Chantal LERUS, Director of Clinical Research    0590 93 46 86 ext (+590)    chantal.lerus@chu-guadeloupe.fr   
Contact: Valerie SOTER, Manager of Reseach    0590 93 46 86 ext (+590)    valerie.soter@chu-guadeloupe.fr   
Principal Investigator: Remy BELLANCE, Neurologist         
Sponsors and Collaborators
Centre Hospitalier Universitaire de Pointe-a-Pitre
Investigators
Study Director: Annie LANNUZEL, Professor, Neurological Hospital University Center of Pointe-à-Pitre

Responsible Party: Centre Hospitalier Universitaire de Pointe-a-Pitre
ClinicalTrials.gov Identifier: NCT03367650     History of Changes
Other Study ID Numbers: RBM-PAP-2013/55
First Posted: December 11, 2017    Key Record Dates
Last Update Posted: December 11, 2017
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Centre Hospitalier Universitaire de Pointe-a-Pitre:
amyotrophic lateral sclerosis
epidemiology
genetic
environmental factor

Additional relevant MeSH terms:
Sclerosis
Amyotrophic Lateral Sclerosis
Motor Neuron Disease
Pathologic Processes
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases